Anupriya Kapoor¹, Ajay Kumar1¹,, Arpit Katiyar² and Shashi Kiran Misra¹*

¹School of pharmaceutical sciences, CSJM University, Kanpur, India
²Sai Meer College of Pharmacy, Kannauj, India

*Corresponding Author: Shashi Kiran Misra, School of pharmaceutical sciences, CSJM University, Kanpur, India.

Received: August 08, 2021; Published: September 23, 2021

Abstract

  Biologic drugs also referred to as biologic response modifiers are powerful medications that comprise small fractions of components like sugars, proteins, or DNA. These drugs include a wide variety of products that are derived from all sorts of living sources including mammals, birds, insects, plants, and even micro-organisms. They offer a new era in the treatment of diseases as they possess the capability to change the manner of operation of biological intracellular and cellular actions. The developments in the field of biologics have added new dimensions in the treatment of dermatological issues. They have emerged as appropriate alternatives for conventional therapies especially in instances where they fail to respond to patient's needs. The therapy including the use of biologics based on a treatment approach that involves the interaction with specific underlying components of the immune system. The review article highlights the biologics used in the treatment of psoriasis since it is a worldwide dermatological problem causing significant pathological and psychological complications.

Keywords: Biologics; Psoriasis; Adalimumab; Etanercept; Secukinumab; Ixekizumab

References

1. Takeshita J., et al. “Psoriasis and comorbid diseases: Epidemiology”. Journal of the American Academy of Dermatology 76 (2017): 377-390.
2. Parisi R., et al. “Global epidemiology of psoriasis: a systematic review of incidence and prevalence”. Journal of Investigative Dermatology 133 (2013): 377-385.
3. Crommelin D., et al. “Pharmaceutical evaluation of biosimilars: important differences from generic low-molecular weight pharmaceuticals”. European Journal of Hospital Pharmacy (EJHP) 1 (2005): 11-17.
4. Declerck PJ., et al. “Biosimilars: controversies as illustrated by rhGH”. Current Medical Research and Opinion 26 (2010).
5. Singh JA., et al. “Adverse effects of biologics: a network meta‐analysis and Cochrane overview”. Cochrane Library: Cochrane Reviews (2011).
6. Mease PJ., et al. “Adalimumab Effectiveness in Psoriatic Arthritis Trial Study Group. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial”. Arthritis and Rheumatism 10 (2005): 3279-3289.
7. Scheinfeld N. “Adalimumab: a review of side effects”. Expert Opinion on Drug Safety 4 (2005): 637-641.
8. van de Kerkhof PC. “Consistent control of psoriasis by continuous long-term therapy: the promise of biological treatments”. Journal of the European Academy of Dermatology and Venereology 20 (2006): 639-650.
9. , et al. “Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial”. Arthritis and Rheumatism 48.1 (2003): 35-45.
10. Moreland L., et al. “Abatacept”. Nature Reviews Drug Discovery 3 (2006): 185-186.
11. Liu XI., et al. “Monoclonal Antibodies and Fc-Fusion Proteins for Pediatric Use: Dosing, Immunogenicity, and Modeling and Simulation in Data Submitted to the US Food and Drug Administration”. Journal of Clinical Pharmacology 8 (2019): 1130-1143.
12. Kumar M., et al. “Pregnancy outcomes following exposure to abatacept during pregnancy”. Seminars in Arthritis and Rheumatism 3 (2015): 351-356.
13. Porter M L., et al. “Update on biologic safety for patients with psoriasis during pregnancy”. International Journal of Women's Dermatology 1 (2017): 21-25.
14. Orban T., et al. “Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial”. Lancet 9789 (2011): 412-419.
15. Brembilla NC., et al. “The IL-17 Family of Cytokines in Psoriasis: IL-17A and Beyond”. Frontiers in Immunology 9 (2018): 1682.
16. Monin L and Gaffen SL. “Interleukin 17 Family Cytokines: Signaling Mechanisms, Biological Activities, and Therapeutic Implications”. Cold Spring Harbor Perspectives in Biology 4 (2018): a028522.
17. Bauer E., et al. “Brodalumab -an IL-17RA monoclonal antibody for psoriasis and psoriatic arthritis”. Expert Opinion on Biological Therapy 6 (2015): 883-893.
18. Goel N abd Stephens S. “Certolizumab pegol”. MAbs2 (2010): 137-147.
19. Fleischmann R., et al. “Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study”. Annals of the Rheumatic Diseases 68 (2009): 805-811.
20. Smolen J., et al. “Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial”. Annals of the Rheumatic Diseases 68 (2009): 797-804.
21. Braun J., et al. “Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly”. Rheumatology (Oxford) 46.6 (2007): 999-1004.
22. Reich K., et al. “Once-weekly administration of etanercept 50 mg improves patient-reported outcomes in patients with moderate-to-severe plaque psoriasis”. Dermatology3 (2009): 239-249.
23. Zhou H. “Clinical pharmacokinetics of etanercept: a fully humanized soluble recombinant tumor necrosis factor receptor fusion protein”. Journal of Clinical Pharmacology5 (2005): 490-497.
24. Goffe B. “Etanercept (Enbrel) -- an update”. Skin Therapy Letter10 (2004): 1-4.
25. Al-Salama ZT and Scott LJ. “Guselkumab: A Review in Moderate to Severe Plaque Psoriasis”. American Journal of Clinical Dermatology 6 (2018): 907-918.
26. Chan TC., et al. “Interleukin 23 in the skin: role in psoriasis pathogenesis and selective interleukin 23 blockade as treatment”. Therapeutic Advances in Chronic Disease 5 (2018): 111-119.
27. Langley RG., et al. “Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial”. British Journal of Dermatology1 (2018): 114-123.
28. Flynn JL., et al. “Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice”. Immunity 2 (1995): 561-572.
29. Mohan VP., et al. “Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology”. Infection and Immunity 69 (2001): 1847-1855.
30. Atzeni F., et al. “Anti-IL-17 Agents in the Treatment of Axial Spondyloarthritis”. Immunotargets Therapy 10 (2021): 141-153.
31. Ramaekers BLT., et al. “Ixekizumab for Treating Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal”. Pharmacoeconomics 8 (2018): 917-927.
32. Blauvelt A., et al. “Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial”. JAMA Dermatology6 (2020): 649-658.
33. Kulig P., et al. “IL-12 protects from psoriasiform skin inflammation”. Nature Communication 7 (2016): 13466.
34. Hamza T., et al. “Interleukin 12 a key immunoregulatory cytokine in infection applications”. International Journal of Molecular Sciences3 (2010): 789-806.
35. Krueger JG., et al. “Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial”. The Journal of Allergy and Clinical Immunology 1 (2015): 116-124.e7.
36. Rich P., et al. “Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study”. British Journal of Dermatology 2 (2013): 402-411.
37. López-Ferrer A., et al. “Secukinumab (AIN457) for the treatment of psoriasis”. Expert Review of Clinical Immunology 11 (2015): 1177-1188.
38. Blauvelt A. “Safety of secukinumab in the treatment of psoriasis”. Expert Opinion on Drug Safety 10 (2006): 1413-1420.
39. Trinchieri G. “Interleukin-12 and the regulation of innate resistance and adaptive immunity”. Nature Review on Immunology2 (2003): 133-46.
40. Xu L., et al. “Cutting edge: regulatory T cells induce CD4+CD25-Foxp3- T cells or are self-induced to become Th17 cells in the absence of exogenous TGF-beta”. Journal of Immunology11 (2007): 6725-6729.
41. Fishwild DM., et al. “High-avidity human IgG kappa monoclonal antibodies from a novel strain of minilocus transgenic mice”. Nature Biotechnology7 (1996): 845-851.
42. Dalgard FJ., et al. “The psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries”. Journal of Investigative Dermatology 135 (2015): 984-991.
43. Kurd SK., et al. “The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study”. Archives of Dermatology 146 (2010): 891-895.
44. Dowlatshahi EA., et al. “The prevalence and odds of depressive symptoms and clinical depression in psoriasis is patients: a systematic review and meta-analysis”. Journal of Investigative Dermatology 134 (2014): 1542-1551.
45. Singh S., et al. “Psoriasis and suicidality: A systematic review and meta-analysis”. Journal of the American Academy of Dermatology 77 (2017): 425-440.

Citation

Citation: Shashi Kiran Misra., et al. “A Review: Biologics in Management of Psoriasis". Acta Scientific Pharmaceutical Sciences 5.10 (2020): 77-83.

Copyright

Copyright: © 2021 Shashi Kiran Misra., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.